Featured
-
-
Letter |
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
A selective inhibitor of the kinetoplastid proteasome (GNF6702) is identified that is highly efficacious in vivo, clearing the parasites that cause leishmaniasis, Chagas disease and sleeping sickness from mice, highlighting the possibility of developing a single class of drugs for these neglected diseases.
- Shilpi Khare
- , Advait S. Nagle
- & Frantisek Supek
-
Article |
Automated design of ligands to polypharmacological profiles
An automated approach designing drug ligands to multi-target profiles (with a 75% prediction success rate) is experimentally validated by the invention of novel ligands tailored to the complex and physiologically-relevant goal of identifying drugs that can specifically target profiles of multiple proteins.
- Jérémy Besnard
- , Gian Filippo Ruda
- & Andrew L. Hopkins